Compare Schwab US Dividend Equity ETF (SCHD) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Schwab US Dividend Equity ETF vs Viatris Inc — how do they compare? Schwab US Dividend Equity ETF trades at $32.8, while Viatris Inc trades at $17.54 (market cap $19.79B). The key difference: Viatris Inc pays a 2.83% dividend while Schwab US Dividend Equity ETF pays none. Which is the better fit depends on your goals.
| SCHD | VTRS | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $33.04 | $17.39 |
52-Week Low | $26.38 | $8.74 |
Market Cap | — | $19.79B |
Enterprise Value | — | $32.00B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SCHD trades at $32.75, down 0.49% today, with technical indicators showing a bullish trend supported by moving averages. The ETF has delivered strong 2026 performance with a 22% year-to-date return and recently surpassed $100 billion in assets under management. Recent news highlights its defensive sector allocation and consistent dividend growth, with a current yield below its historical average due to price appreciation.
The outlook remains positive given SCHD's quality screening methodology and institutional inflows, though risks include interest rate sensitivity and market volatility. Analyst sentiment is bullish with the fund positioned as a defensive income play with capital appreciation potential in uncertain markets.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
